Interventional - Drug
Despite the use of aspirin, there is still a risk of ischaemic events after percutaneous coronary intervention (PCI).
We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI.
The objective of the PCI-CURE study was to determine if, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after a patient undergoes percutaneous coronary intervention (PCI) is superior to a strategy of no pretreatment and short-term therapy for only four weeks after PCI.
Patients with non-ST-elevation acute coronary syndrome undergoing PCI in our CURE study were randomly assigned double-blind treatment with clopidogrel or placebo.
A composite of cardiovascular death, myocardial infarction, or urgent target-vessel revascularisation within 30 days of PCI.
We concluded that in patients with acute coronary syndrome receiving aspirin, a strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events, compared with placebo.
Interventional - Drug
1998 - 2001
Shamir Mehta is a Senior Scientist with the Acute Coronary Syndrome and Interventional Cardiology research program at PHRI, a Professor of Medicine at McMaster University, and Director of the Interventional Cardiology program at Hamilton Health Sciences. His research focuses on the role and timing of invasive therapies in patients with acute ischemic heart disease, and the evaluation of novel antiplatelet and anticoagulant therapies in these patients.
He has led several large pragmatic randomized trials evaluating invasive interventional strategies in patients with acute coronary syndromes. He has also lead multinational randomized trials evaluating novel antiplatelet and anticoagulant therapies to improve outcomes in patients experiencing a heart attack.
Shamir Mehta has published 127 original research papers in several medical journals including The New England Journal of Medicine, The Lancet, JAMA, and Circulation. His success in research has earned him a coveted Canada’s Top 40 under 40TM award in 2004, and he has received a Canadian Institutes of Health Research New Investigator Career Award.
Back To Top